|
US2021023165A1
|
|
Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment
|
|
AU2019245436A1
|
|
Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment
|
|
US2018092836A1
|
|
Ophthalmic drug sustained release formulation and uses thereof
|
|
CN110475543A
|
|
Eye medicinal extended release preparation and application thereof
|
|
EP3474794A1
|
|
Static pin insertion tool for lacrimal implant
|
|
US2014025022A1
|
|
Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
|
|
EP2844224A1
|
|
Drug delivery system for treating open angle glaucoma and ocular hypertension
|
|
CN107669399A
|
|
Sustained release delivery activating agent is to treat glaucoma and Bulbi hypertonia
|
|
EP2389221A2
|
|
Sustained released delivery of one or more agents
|
|
EP2276471A2
|
|
Composite lacrimal insert and related methods
|
|
NZ595623A
|
|
A drug insert surrounded by a sheath to expose a polymer containing a drug to surrounding tissues or an eye
|
|
AU2005269988A1
|
|
Treatment medium delivery device and methods for delivery
|
